depression
AstraZeneca posts drug failures, takes $382m hit
December 20, 2011Research and Development, Sales and Marketing AstraZeneca, depression, ovarian cancer
AstraZeneca has taken a major blow to its late stage pipeline, with one of its key cancer drugs now being …
Kantar Health Launches Global Health and Wellness Quarterly Update
July 12, 2011Sales and Marketing Kantar Health, depression, emerging markets, information, newsletter, work productivity
The inaugural issue of Kantar Health’s Global Health and Wellness Update is now available. This is a quarterly newsletter sharing …
Forest depression candidate struggles against placebo
March 1, 2011Research and Development Forest, Forest Laboratories, Gedeon Richter, cariprazine, depression, major depressive disorder
An investigational antipsychotic drug being developed by Forest Laboratories and Budapest-based Gedeon Richter has failed to prove itself in phase …
AZ-Targacept depression candidate moves into phase IIb
February 9, 2011Research and Development AZ, AstraZeneca, TC-5214, Targacept, depression, major depressive disorder
AstraZeneca and Targacept have begun a phase IIb trial of TC-5214 as a ‘switch’ monotherapy for patients with depression. The …
Digital Pharma: Pfizer puts mental health diagnosis tools online
July 26, 2010Medical Communications Digital Pharma blog, Pfizer, depression, digital patients
Pfizer has put two widely used mental health assessment tools online for the public to use. It aims to improve …
AstraZeneca and Targacept begin depression trials
June 24, 2010Research and Development AstraZeneca, Targacept, depression
AstraZeneca and Targacept have begun enrolling patients in phase III trials for TC-5214, a new treatment for depression. The new …
GSK agrees generic deal on Malarone
April 13, 2010Sales and Marketing GSK, depression, generics
Generic versions of two GlaxoSmithKline products have received the green light for launch in the US. Mylan has been given …
AZ licences late-stage depression candidate
December 8, 2009Sales and Marketing AZ, Targacept, depression
AstraZeneca is to pay $200 million up front for rights to a late-stage developmental drug aimed at sufferers from depression …
Wyeth pulls European application for Ellefore
October 16, 2008Sales and Marketing EU, Pfizer, depression
The European future of Wyeth’s depression treatment Ellefore has been thrown into doubt after the pharma company withdrew its application …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
